RankAlpha logo
Back to Rankings

LLY

Eli Lilly andB
NYSE / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
View Chart
Current thesis
The structured prior remains positive and the primary-source evidence is strong: Q1 2026 growth was exceptional, guidance was raised, and the company highlighted both commercial and pipeline progress in obesity and cardiometabolic health. With the median analyst target in the packet near $1,264.9 versus the $1,208.12 anchor price, the base case still points to modest upside rather than a fresh re-rating.
Posture
Constructive
Lead driver
Value
What changed
Value remains the lead driver in the composite, 7D delta -0.2.
What can break
High expectations after a 56% revenue growth quarter and raised guidance leave less room for future upside surprise if launch, reimbursement, or supply execution softens. [#SEC-8K-2026-04-30]
Momentum
50
Value
59
Sentiment
53
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $1,265.00 · Bull $1,360.00 · Bear $1,085.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-06-29 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade B · Constructive
Confidence Medium · Net Neutral
Target $1,306.96
Why
Momentum50 · Δ7d -20.9
Value59 · Δ7d -0.2
Sentiment53 · Δ7d -2.8
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Value · See fundamentals
Momentum
50
26% active weight
Current posture
7d trendFlat
Δ7d
-20.9
Δ21d
-37.2
Value
59
39% active weight
Current posture
7d trendFlat
Δ7d
-0.2
Δ21d
+0.0
Sentiment
53
34% active weight
Current posture
7d trendSoftening
Δ7d
-2.8
Δ21d
+7.4
Why this grade

Composite grade B. Momentum 50.3 / Value 59.0 / Sentiment 52.5

Fundamentals (TTM)
As of 2026-07-17
Market Cap
$1.11T
Beta
0.39
Shares Out
941.74M
P/E (TTM)
50.9
P/S (TTM)
16.57
P/FCF (TTM)
800.77
Rev YoY
+55.5%
EPS YoY
+169.4%
Gross Margin
+82.8%
Op Margin
+38.8%
Net Debt
$36.6B
Current Ratio
1.50
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology